Investigational chemotherapy-free regimen of amivantamab plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk…
BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic…
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma…
Local startup Oncobiotix to receive $100,000 to advance cancer and microbiome researchCALGARY, Alberta, May 31, 2024 (GLOBE NEWSWIRE) -- The…
MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks…
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - May 31, 2024) - Cosmo Pharmaceuticals N.V. (SIX:…
AI workflow enhances precision of progression-free survival estimates in metastatic breast cancer, enabling more effective and personalized treatmentsCAMBRIDGE, Mass.--(BUSINESS WIRE)--nference,…
OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced…
Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued…
Backed by decades of longevity science, platform measures “biological noise” to determine age and fitness of key body systems aimed…